Psych Vivas · General adult psychiatry — psychotic disorders
Delusional disorder — structured clinical viva
Fellowship viva on somatic delusional disorder vs schizophrenia, engagement without collusion, iatrogenic harm prevention, antipsychotic plan, and evidence limits.
On this page & tools
Target exams
Interpretation
Reveal interpretation
Working diagnosis. Delusional disorder, somatic subtype (infestation belief), duration years, no prominent hallucinations, relatively preserved occupational function — partial psychosis rather than multi-domain schizophrenia. Differential includes organic skin disease (rule out once), substance use, BDD/illness anxiety with poor insight, and late medical/neurocognitive disease if new cognitive signs appear.[1][2]
Why not schizophrenia. Absence of broader Criterion A (prominent voices, disorganisation, negative symptom syndrome) and relatively preserved role function outside the somatic theme favour delusional disorder over schizophrenia.[2]
Structured viva answers
Reveal structured answers
Engagement. Validate distress and sleep disruption; do not collude (“yes, parasites”) and do not ridicule specimens. Negotiate shared goals: itch control, sleep, reduce harmful self-treatments, coordinated care. Frame medication as reducing mental pressure and preoccupation so she can function — not as proof the belief is false on day one.[6][4]
Liaison and harm prevention. One thorough medical/dermatology review to exclude genuine pathology, then psychiatric leadership of the care plan to prevent endless biopsies/procedures. Agree a letter framework with GP/dermatology: investigate red flags, avoid non-indicated invasive interventions.[5][4]
Pharmacotherapy. Offer SGA trial with monitoring — e.g. aripiprazole 5–10 mg daily toward 10–15 mg, or risperidone 1–2 mg titrating carefully, or olanzapine 5–10 mg if sedation/itch sleep disruption dominates, with metabolic/EPS/prolactin/ECG-risk monitoring as indicated. Historical pimozide is an exam pearl with QTc caution, not automatic modern first line. State Cochrane: sparse high-quality DD-specific RCTs.[3][5][6][4]
Success metrics. Reduced specimen-collecting, less self-excoriation/self-treatment, better sleep, fewer emergency dermatology attendances — belief may persist partially.[6][1]
Risks. Suicide if despair when belief falters; iatrogenic medical harm; antipsychotic side effects; disengagement if alliance broken.[4]
References
- [1]Opjordsmoen S Delusional disorder as a partial psychosis Schizophr Bull, 2014.PMID 24421383
- [2]González-Rodríguez A, Seeman MV Differences between delusional disorder and schizophrenia: A mini narrative review World J Psychiatry, 2022.PMID 35663297
- [3]Skelton M, Khokhar WA, Thacker SP Treatments for delusional disorder Cochrane Database Syst Rev, 2015.PMID 25997589
- [4]Galletly C, Castle D, Dark F, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders Aust N Z J Psychiatry, 2016.PMID 27106681
- [5]González-Rodríguez A, Monreal JA, Natividad M, et al. Seventy Years of Treating Delusional Disorder with Antipsychotics: A Historical Perspective Biomedicines, 2022.PMID 36552037
- [6]Manschreck TC, Khan NL Recent advances in the treatment of delusional disorder Can J Psychiatry, 2006.PMID 16989110